Putting artificial caps on profitability for drugs that add real value to patients is not the answer.
from Forbes Real Time https://www.forbes.com/sites/johnlamattina/2018/02/12/how-much-profit-should-novartis-earn-by-curing-a-childhood-leukemia/
via IFTTT
No comments:
Post a Comment